zolpidem has been researched along with Absence Seizure in 33 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The SNR effects on seizures are site-specific within the SNR and developmentally regulated." | 5.30 | Regional and age specific effects of zolpidem microinfusions in the substantia nigra on seizures. ( Löscher, W; Moshé, SL; Velísková, J, 1998) |
| " Additionally, noneffective doses of either KATP channel opener (cromakalim) or nonselective μ-opioid receptor agonist (morphine) in combination with a noneffective dose of zolpidem exerted a significant anticonvulsive effect on PTZ-induced seizures in mice." | 3.83 | Involvement of ATP-sensitive potassium channels and the opioid system in the anticonvulsive effect of zolpidem in mice. ( Amiri, S; Dehdashtian, A; Dehpour, AR; Ghasemi, M; Ostadhadi, S; Sheikhi, M; Shirzadian, A, 2016) |
| "Clobazam (CLB), a 1,5-benzodiazepine (BZD), was FDA-approved in October 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older." | 3.80 | Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes. ( Ebert, B; Jensen, HS; Lee, D; Nichol, K, 2014) |
| " In the present study, we examined the ability of diazepam to reduce pentylenetetrazoLe (PTZ)-induced and maximal electroshock (MES)-induced seizures in mice containing point mutations in single (alpha1H101R, alpha2H101R or alpha5H105R) or multiple (alpha125H-->R) alpha subunits that render the resulting GABA(A) receptors diazepam-insensitive." | 3.74 | Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. ( Atack, JR; Bull, S; Dawson, GR; Fradley, RL; Garrett, EM; Goodacre, SC; Guscott, MR; Hallett, DJ; Newman, RJ; O'Meara, GF; Reynolds, DS; Rosahl, TW; Wafford, KA; Whiting, PJ, 2007) |
| " In vivo tolerance was measured by a reduced ability of the alpha(1)-subunit-selective agonist zolpidem to suppress pentylenetetrazole-induced seizures." | 3.70 | Antagonist-induced reversal of functional and structural measures of hippocampal benzodiazepine tolerance. ( Chen, S; Kometiani, P; Lilly, SM; Rosenberg, HC; Tietz, EI; Zeng, XJ, 1999) |
| "Zolpidem is an imidazopyridine nonbenzodiazepine hypnotic drug with a high affinity to the α1 subunit of the gamma amino butyric acid A receptor It is the first pharmacological option in the short-term management of sleep-onset insomnia." | 1.48 | Severe Chronic Abuse of Zolpidem in Refractory Insomnia. ( Bianco, G; Castelnovo, A; Chiaro, G; Maffei, P; Manconi, M, 2018) |
| "Zolpidem is a widely used hypnotic drug acting via benzodiazepine binding sites on GABA(A) receptors." | 1.36 | Zolpidem is a potent anticonvulsant in adult and aged mice. ( Pericić, D; Vlainić, J, 2010) |
| "After repeated treatment the PTZ seizure threshold was not different between the two drugs, while differences in sedation became larger than after the acute treatment." | 1.35 | Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam. ( Pericić, D; Vlainić, J, 2009) |
| "Zolpidem is a short acting hypnotic drug belonging to imidazopyridine family." | 1.34 | Seizure following sudden zolpidem withdrawal. ( Cubała, WJ; Landowski, J, 2007) |
| "Zolpidem is a non-benzodiazepine hypnotic drug, acts selectively through omega 1 receptors of GABAA." | 1.33 | Zolpidem at supratherapeutic doses can cause drug abuse, dependence and withdrawal seizure. ( Khandelwal, DC; Sethi, PK, 2005) |
| " To assess pharmacodynamic and neurochemical effects of zolpidem, open-field behavior, pentylenetetrazole-induced seizure threshold and benzodiazepine receptor binding in vitro were evaluated in the same animal following a single dose of zolpidem." | 1.33 | Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses. ( Fahey, JM; Grassi, JM; Greenblatt, DJ; Reddi, JM, 2006) |
| "The SNR effects on seizures are site-specific within the SNR and developmentally regulated." | 1.30 | Regional and age specific effects of zolpidem microinfusions in the substantia nigra on seizures. ( Löscher, W; Moshé, SL; Velísková, J, 1998) |
| "Zaleplon was more potent than zolpidem but the maximal effect of zolpidem for increasing the latency to isoniazid-induced convulsions was greater than that of zaleplon." | 1.29 | Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. ( Morel, E; Perrault, G; Sanger, DJ, 1996) |
| "Zolpidem is a new, short-acting hypnotic of imidazopyridine structure which binds selectively to a subpopulation of receptors involved in the action of benzodiazepines [omega 1 (BZ1) sites of the gamma-aminobutyric acidA receptors]." | 1.28 | Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. ( Morel, E; Perrault, G; Sanger, DJ; Zivkovic, B, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 11 (33.33) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 7 (21.21) | 24.3611 |
| 2020's | 3 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, ED | 1 |
| Diaz-Arauzo, H | 1 |
| Huang, Q | 1 |
| Reddy, MS | 1 |
| Ma, C | 1 |
| Harris, B | 1 |
| McKernan, R | 1 |
| Skolnick, P | 1 |
| Cook, JM | 1 |
| Costanzo, A | 1 |
| Guerrini, G | 1 |
| Ciciani, G | 1 |
| Bruni, F | 1 |
| Costagli, C | 1 |
| Selleri, S | 1 |
| Besnard, F | 1 |
| Costa, B | 1 |
| Martini, C | 1 |
| Malmberg-Aiello, P | 1 |
| Plech, T | 1 |
| Kaproń, B | 1 |
| Luszczki, JJ | 1 |
| Paneth, A | 1 |
| Siwek, A | 1 |
| Kołaczkowski, M | 1 |
| Żołnierek, M | 1 |
| Nowak, G | 1 |
| Mashiana, MK | 1 |
| Irfanullah, Z | 1 |
| Khawaja, HI | 1 |
| Khawaja, AZ | 1 |
| Khawaja, IS | 1 |
| Russo, AD | 1 |
| Hodgman, M | 1 |
| Calleo, V | 1 |
| Castillo, JL | 1 |
| Chiaro, G | 1 |
| Castelnovo, A | 1 |
| Bianco, G | 1 |
| Maffei, P | 1 |
| Manconi, M | 1 |
| Jensen, HS | 1 |
| Nichol, K | 1 |
| Lee, D | 1 |
| Ebert, B | 1 |
| Sheikhi, M | 1 |
| Shirzadian, A | 1 |
| Dehdashtian, A | 1 |
| Amiri, S | 1 |
| Ostadhadi, S | 1 |
| Ghasemi, M | 1 |
| Dehpour, AR | 1 |
| Auta, J | 2 |
| Impagnatiello, F | 1 |
| Kadriu, B | 1 |
| Guidotti, A | 2 |
| Costa, E | 2 |
| Vlainić, J | 2 |
| Pericić, D | 2 |
| Belozertsev, IuA | 1 |
| Shchelkanova, OA | 1 |
| Belozertsev, FIu | 1 |
| Iuntsev, SV | 1 |
| Kralic, JE | 1 |
| O'Buckley, TK | 1 |
| Khisti, RT | 1 |
| Hodge, CW | 1 |
| Homanics, GE | 1 |
| Morrow, AL | 3 |
| Kliethermes, CL | 1 |
| Metten, P | 1 |
| Belknap, JK | 1 |
| Buck, KJ | 1 |
| Crabbe, JC | 1 |
| Sethi, PK | 1 |
| Khandelwal, DC | 1 |
| Fahey, JM | 1 |
| Grassi, JM | 1 |
| Reddi, JM | 1 |
| Greenblatt, DJ | 1 |
| Cubała, WJ | 2 |
| Landowski, J | 1 |
| Fradley, RL | 1 |
| Guscott, MR | 1 |
| Bull, S | 1 |
| Hallett, DJ | 1 |
| Goodacre, SC | 1 |
| Wafford, KA | 1 |
| Garrett, EM | 1 |
| Newman, RJ | 1 |
| O'Meara, GF | 1 |
| Whiting, PJ | 1 |
| Rosahl, TW | 1 |
| Dawson, GR | 1 |
| Reynolds, DS | 1 |
| Atack, JR | 1 |
| Huang, MC | 1 |
| Lin, HY | 1 |
| Chen, CH | 1 |
| Wichowicz, HM | 1 |
| Gericke, CA | 1 |
| Ludolph, AC | 1 |
| Romeo, E | 1 |
| Kozikowski, A | 1 |
| Ma, D | 1 |
| Sanger, DJ | 3 |
| Morel, E | 3 |
| Perrault, G | 3 |
| Devaud, LL | 1 |
| Bucci, D | 1 |
| Smith, FD | 1 |
| Cannizzaro, C | 1 |
| Cannizzaro, E | 1 |
| Gagliano, M | 1 |
| Mangiapane, N | 1 |
| Xiao, X | 1 |
| McCown, TJ | 1 |
| Li, J | 1 |
| Breese, GR | 1 |
| Samulski, RJ | 1 |
| Gilbert, DL | 1 |
| Staats, PS | 1 |
| Velísková, J | 1 |
| Löscher, W | 1 |
| Moshé, SL | 1 |
| Tietz, EI | 1 |
| Zeng, XJ | 1 |
| Chen, S | 1 |
| Lilly, SM | 1 |
| Rosenberg, HC | 1 |
| Kometiani, P | 1 |
| Zivkovic, B | 2 |
33 other studies available for zolpidem and Absence Seizure
| Article | Year |
|---|---|
Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423)
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Binding, Competitive; Carbolines; Cell Line; Cerebral | 1998 |
Benzodiazepine receptor ligands. 7. Synthesis and pharmacological evaluation of new 3-esters of the 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide. 3-(2-Thienylmethoxycarbonyl) derivative: an anxioselective agent in rodents.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Avoidance Learning; Cell Line; Cerebral Cortex; Cycli | 2002 |
Studies on the anticonvulsant activity of 4-alkyl-1,2,4-triazole-3-thiones and their effect on GABAergic system.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Electroshock; Male; Mice; Molecular Stru | 2014 |
Case of Seizures With Sudden Discontinuation of Zolpidem.
Topics: Humans; Hypnotics and Sedatives; Seizures; Zolpidem | 2021 |
Seizures secondary to zolpidem withdrawal.
Topics: Adult; Humans; Male; Seizures; Sleep Aids, Pharmaceutical; Substance Withdrawal Syndrome; Zolpidem | 2021 |
[Epileptic seizures after zolpidem withdrawal].
Topics: Epilepsy; Humans; Hypnotics and Sedatives; Seizures; Zolpidem | 2020 |
Severe Chronic Abuse of Zolpidem in Refractory Insomnia.
Topics: Aged; Anticonvulsants; Chronic Disease; Clonazepam; Female; Hospitalization; Humans; Levetiracetam; | 2018 |
Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes.
Topics: Allosteric Site; Animals; Anticonvulsants; Benzodiazepines; Binding Sites; Brain; Clobazam; Clonazep | 2014 |
May I Have Another? - Medication Error.
Topics: Adult; Humans; Hypnotics and Sedatives; Male; Medication Errors; Pyridines; Seizures; Zolpidem | 2015 |
Involvement of ATP-sensitive potassium channels and the opioid system in the anticonvulsive effect of zolpidem in mice.
Topics: Analgesics, Opioid; Animals; Anticonvulsants; Cromakalim; Dose-Response Relationship, Drug; Drug The | 2016 |
Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem.
Topics: Animals; Anticonvulsants; Behavior, Animal; Benzodiazepines; Bicuculline; Diazepam; Differential Thr | 2008 |
Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam.
Topics: Animals; Anticonvulsants; Convulsants; Diazepam; Dose-Response Relationship, Drug; Drug Administrati | 2009 |
Zolpidem is a potent anticonvulsant in adult and aged mice.
Topics: Age Factors; Aging; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interact | 2010 |
[Comparative evaluation of the hypnotic drugs under conditions of brain injury].
Topics: Animals; Azabicyclo Compounds; Brain Injuries; Hypnotics and Sedatives; Hypoxia; Injections, Intrape | 2012 |
GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Behavior, Animal; Benzodiazepines; Chlorides; Diazepa | 2002 |
Selection for pentobarbital withdrawal severity: correlated differences in withdrawal from other sedative drugs.
Topics: Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Central Nervous System Depressants | 2004 |
Zolpidem at supratherapeutic doses can cause drug abuse, dependence and withdrawal seizure.
Topics: Adult; Humans; Hypnotics and Sedatives; Male; Panic Disorder; Pyridines; Risk Factors; Seizures; Sle | 2005 |
Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses.
Topics: Animals; Anticonvulsants; Binding, Competitive; Convulsants; Dose-Response Relationship, Drug; Fluni | 2006 |
Seizure following sudden zolpidem withdrawal.
Topics: Adult; Female; Humans; Hypnotics and Sedatives; Mental Disorders; Pyridines; Seizures; Substance Wit | 2007 |
Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands.
Topics: Animals; Anticonvulsants; Benzodiazepines; Binding Sites; Convulsants; Diazepam; Electroshock; GABA- | 2007 |
Dependence on zolpidem.
Topics: Adult; Female; Humans; Hypnotics and Sedatives; Pyridines; Seizures; Sleep Wake Disorders; Substance | 2007 |
Dependence on zolpidem: is pharmacokinetics important?
Topics: Dose-Response Relationship, Drug; Humans; Hypnotics and Sedatives; Inactivation, Metabolic; Metaboli | 2008 |
Chronic abuse of zolpidem.
Topics: Adult; Humans; Male; Pyridines; Seizures; Substance Withdrawal Syndrome; Substance-Related Disorders | 1994 |
Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl-3-indoleacetamide and imidazopyridine derivatives.
Topics: Aggression; Allosteric Regulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Behavior, Animal; | 1993 |
Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem.
Topics: Acetamides; Analysis of Variance; Animals; Chlordiazepoxide; Convulsants; Discrimination Learning; E | 1996 |
GABAA and NMDA receptor subunit mRNA expression in ethanol dependent rats.
Topics: Alcoholism; Animals; Azides; Base Sequence; Benzodiazepines; Cerebellum; Cerebral Cortex; Dizocilpin | 1994 |
Behavioural responsiveness to picrotoxin and desipramine in adult rats prenatally exposed to different benzodiazepine receptor agonists.
Topics: Adrenergic Uptake Inhibitors; Alprazolam; Animals; Behavior, Animal; Desipramine; Diazepam; Female; | 1995 |
Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity.
Topics: Animals; Antisense Elements (Genetics); Dependovirus; Disease Susceptibility; Female; Gene Transfer | 1997 |
Seizure after withdrawal from supratherapeutic doses of zolpidem tartrate, a selective omega I benzodiazepine receptor agonist.
Topics: Adult; GABA-A Receptor Agonists; Humans; Hypnotics and Sedatives; Male; Pyridines; Seizures; Substan | 1997 |
Regional and age specific effects of zolpidem microinfusions in the substantia nigra on seizures.
Topics: Aging; Animals; Anticonvulsants; Convulsants; Flurothyl; Hypnotics and Sedatives; Male; Microinjecti | 1998 |
Antagonist-induced reversal of functional and structural measures of hippocampal benzodiazepine tolerance.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Autoradiography; Behavior, Animal; Benzodiazepines; C | 1999 |
Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem.
Topics: Animals; Drug Tolerance; Electroshock; Hypnotics and Sedatives; Injections, Intraperitoneal; Isoniaz | 1992 |
The interaction between zolpidem and beta-CMC: a clue to the identification of receptor sites involved in the sedative effect of zolpidem.
Topics: Animals; Binding Sites; Carbolines; Drug Synergism; Locomotion; Mice; Muscles; Pyridines; Rats; Rats | 1988 |